冠状动脉支架内再狭窄的治疗现状及进展  

Current Treatment and Prospect of In-stent Restenosis

作　　者：邓婵翠 石蓓[1] 刘志江[1] 

机构地区：[1]遵义医学院第一附属医院心血管内科,贵州遵义563003

出　　处：《心血管病学进展》2015年第6期747-751,共5页Advances in Cardiovascular Diseases

摘　　要：药物洗脱支架在显著降低再狭窄发生率的同时,增加了晚期支架内血栓发生风险及加速了新生内膜动脉粥样硬化。过去认为再狭窄的发生主要是由于新生内膜过度增殖,但新近研究发现,新生动脉粥样硬化斑块可能扮演了重要的病理生理作用,而晚期支架内血栓形成和新生内膜动脉粥样硬化是晚期支架失败的重要原因。现对近年来冠状动脉支架内再狭窄的治疗现状及进展做一综述。Drug-eluting stent have dramatically reduced restenosis rates,however,their use has been associated with an increased risk of late or very late stent thrombosis and accelerated neointimal atherosclerosis. In-stent restenosis mainly results from aggressive neointimal proliferation,but recent data also suggests that in-stent neoatherosclerosis may play an important pathophysiological role,while late stent thrombosis and neointimal atherosclerosis are major contributors to late stent failure. In this review,we discuss currently available therapeutic strategies and prospects for the management of patients with in-stent restenosis.

关 键 词：冠状动脉再狭窄 新生动脉粥样硬化斑块 支架 现状 

分 类 号：R541.4[医药卫生—心血管疾病]